2142 — HBM Holdings Share News
0.000.00%
Last trade - 00:00- HK$9.03bn
- HK$6.91bn
- $157.98m
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study
Brief: HBM Holdings Appoints Youchen Chen And Ian Yi Liu As Executive Directors
China's HBM Holdings H1 revenue rises on progress on mid-late clinical stage programs
Brief: HBM Holdings Says Nmpa Approves Ind Application For Hbm7004 For Advanced Solid Tumors
Brief: HBM Holdings Enters Strategic Collaboration With China National Pharmaceutical Group On Biologics Research And Development
Brief: HBM Holdings Expects HY Revenue $120 Million-$125 Million
Brief: Hbm Says Co And Biomap Enter Global Strategic Partnership For AI-Driven Biologics
China's Harbour BioMed to focus on another patent case after $20 million damages award
Brief: HBM Holdings Says Jury Returns Verdict In Favor Of Harbour Antibodies Against Amgen IN U.S. Patent Case
Brief: HBM Holdings Says NMPA Accepts IND Application For HBM7004 For Advanced Solid Tumors
China's HBM climbs on regulator's nod on application of new cancer drug
Brief: HBM Holdings Says Independent Non-Executive Director Receives Case Filing Notice From CSRC
Sichuan Kelun-Biotech jumps most in near 12 months on drug application
Brief: HBM Holdings Says NMPA Approved Investigational New Drug Application For HBM7575 (SKB575) For Atopic Dermatitis
HK-listed HBM jumps on licensing deal with Solstice on oncology drug
Brief: HBM Holdings Announces License And Equity Partnership Deal With Solstice Oncology For HBM4003